-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ophthalmology is a discipline that studies diseases that occur in the visual system, including the eyeball and its associated tissues.
Generally, it can be divided into anterior and posterior diseases according to the location of the disease
.
In recent years, due to the aging of the population, the widespread use of electronic products, and the increased intensity of eye use, the global incidence of various eye diseases is on the rise
.
In this context, the ensuing global demand for ophthalmic treatment has also shown a continuous growth trend
.
In the face of the huge market size of ophthalmic drugs, domestic pharmaceutical companies certainly do not want to miss it.
In recent years, a large number of pharmaceutical companies in China have begun to flood into the new ophthalmic drug track
.
It is worth mentioning that there has been a lot of good news in the research and development of new ophthalmic drugs from many pharmaceutical companies recently
.
For example, on February 17, the China Drug Clinical Trial Registration and Information Publicity Platform showed that Zhaoke Ophthalmology Co.
, Ltd.
has launched a Phase 3 clinical trial of atropine sulfate eye drops (NVK-002) for delaying the progression of myopia in children.
A total of 526 patients were enrolled from China
.
According to public information, NVK-002 is a sterile, preservative-free, low-concentration atropine eye drop developed by Nevakar, which is intended to be developed for the control of myopia progression in children and adolescents
.
In October 2020, Zhaoke Ophthalmology and Nevakar Company reached a cooperation and obtained the exclusive development and commercialization license rights of NVK-002 in Greater China, South Korea and several Southeast Asian countries and regions
.
At present, the drug has entered the phase 3 clinical trial stage worldwide
.
In addition to the above-mentioned drugs, according to data, there are currently more than 30 new domestic ophthalmic drugs (22 category 1 new drugs) that are in the stage of clinical application and above, of which 3 new drugs from Hengrui are expected to be launched; and in terms of generic drugs, 10 No first imitation of ophthalmic drugs has been approved yet, and Kelun, Yangzijiang, etc.
have been deployed; in addition, 10 eye drops have been reviewed by companies, and 4 have been included in the national procurement
.
Analysts believe that, from the data point of view, with the continuous increase of domestic developers' investment in ophthalmic drug research and development and the continuous improvement of innovation capabilities, local pharmaceutical companies have begun to make breakthroughs in the field of ophthalmic treatment, and more domestic companies with innovative points and combination therapy.
Drugs will gradually emerge
.
In the future, under the background of continuous favorable policies and huge space for the demand market, the entire ophthalmic industry is expected to show a strong growth trend
.
It is estimated that by 2025, the size of China's ophthalmology market may at least exceed 310 billion
.
This is undoubtedly a mouth-watering big cake, and it will also attract more and more companies to enter the market
.
It should be noted that as more and more pharmaceutical companies deploy in this field, the industry believes that domestic companies must also continue to strengthen innovation, rely on high-tech to compete with foreign companies, and meet the needs of the domestic ophthalmology market.
Unmet clinical needs
.
It is understood that from the current development trend of the ophthalmology track, the homogenization of relatively low-end vision care products is gradually becoming serious, and it is difficult to become the competitive advantage of various companies.
Therefore, the future competition in the ophthalmic medical field may be mainly reflected in relying on high-tech High-end market with technological advantages
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Generally, it can be divided into anterior and posterior diseases according to the location of the disease
.
In recent years, due to the aging of the population, the widespread use of electronic products, and the increased intensity of eye use, the global incidence of various eye diseases is on the rise
.
In this context, the ensuing global demand for ophthalmic treatment has also shown a continuous growth trend
.
In the face of the huge market size of ophthalmic drugs, domestic pharmaceutical companies certainly do not want to miss it.
In recent years, a large number of pharmaceutical companies in China have begun to flood into the new ophthalmic drug track
.
It is worth mentioning that there has been a lot of good news in the research and development of new ophthalmic drugs from many pharmaceutical companies recently
.
For example, on February 17, the China Drug Clinical Trial Registration and Information Publicity Platform showed that Zhaoke Ophthalmology Co.
, Ltd.
has launched a Phase 3 clinical trial of atropine sulfate eye drops (NVK-002) for delaying the progression of myopia in children.
A total of 526 patients were enrolled from China
.
According to public information, NVK-002 is a sterile, preservative-free, low-concentration atropine eye drop developed by Nevakar, which is intended to be developed for the control of myopia progression in children and adolescents
.
In October 2020, Zhaoke Ophthalmology and Nevakar Company reached a cooperation and obtained the exclusive development and commercialization license rights of NVK-002 in Greater China, South Korea and several Southeast Asian countries and regions
.
At present, the drug has entered the phase 3 clinical trial stage worldwide
.
In addition to the above-mentioned drugs, according to data, there are currently more than 30 new domestic ophthalmic drugs (22 category 1 new drugs) that are in the stage of clinical application and above, of which 3 new drugs from Hengrui are expected to be launched; and in terms of generic drugs, 10 No first imitation of ophthalmic drugs has been approved yet, and Kelun, Yangzijiang, etc.
have been deployed; in addition, 10 eye drops have been reviewed by companies, and 4 have been included in the national procurement
.
Analysts believe that, from the data point of view, with the continuous increase of domestic developers' investment in ophthalmic drug research and development and the continuous improvement of innovation capabilities, local pharmaceutical companies have begun to make breakthroughs in the field of ophthalmic treatment, and more domestic companies with innovative points and combination therapy.
Drugs will gradually emerge
.
In the future, under the background of continuous favorable policies and huge space for the demand market, the entire ophthalmic industry is expected to show a strong growth trend
.
It is estimated that by 2025, the size of China's ophthalmology market may at least exceed 310 billion
.
This is undoubtedly a mouth-watering big cake, and it will also attract more and more companies to enter the market
.
It should be noted that as more and more pharmaceutical companies deploy in this field, the industry believes that domestic companies must also continue to strengthen innovation, rely on high-tech to compete with foreign companies, and meet the needs of the domestic ophthalmology market.
Unmet clinical needs
.
It is understood that from the current development trend of the ophthalmology track, the homogenization of relatively low-end vision care products is gradually becoming serious, and it is difficult to become the competitive advantage of various companies.
Therefore, the future competition in the ophthalmic medical field may be mainly reflected in relying on high-tech High-end market with technological advantages
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
